Pharma Stability: Insights, Guidelines, and Expertise
Regulators like the USFDA and ICH expect pharmaceutical companies to follow the ALCOA+ principles: data must be Attributable, Legible, Contemporaneous, Original, Accurate, and also Complete, Consistent, Enduring, and Available. QA and IT must work together to uphold these principles in all aspects of stability testing and documentation.
Click to read the full article.
Cross-site testing involves transferring samples and data between multiple facilities, often in different regions or countries. Common risk points include:
Click to read the full article.
Stability testing in the pharmaceutical industry generates vast amounts of data, which must be preserved, verified, and audited throughout a product’s lifecycle. Without a proper data governance framework, companies risk losing control over critical information, exposing themselves to regulatory penalties and potential product recalls. A well-structured governance system ensures that stability data is accurate, attributable, and aligned with GMP guidelines.
Click to read the full article.
Validated software ensures that the electronic systems used in stability testing consistently function as intended. Any failure or incorrect output in these systems could lead to:
Click to read the full article.
Audit trails are a critical feature in computerized systems used for stability studies. They provide a secure, time-stamped record of who performed an action, what was changed, and why. Ensuring their completeness and accuracy is essential for regulatory compliance and data integrity under USFDA and other global guidelines.
Click to read the full article.
In pharmaceutical development, raw stability data represents the foundation for determining a product’s shelf life, release specifications, and long-term safety. Improper storage, data loss, or unauthorized access can result in regulatory action, product recalls, or even public health risks.
Click to read the full article.
In the pharmaceutical industry, stability data is crucial for ensuring product quality over time. From raw data capture to final reporting, every phase of the data lifecycle must be meticulously documented. Regulatory authorities like the USFDA, EMA, and CDSCO expect companies to implement lifecycle-based data governance frameworks that ensure traceability, integrity, and completeness.
Click to read the full article.
Anonymous changes refer to any data edits, deletions, or insertions in a stability database where the system fails to log the user identity associated with the action. This directly violates the ALCOA principles—particularly the Attributable and Auditability criteria.
Click to read the full article.